Published in J Clin Invest on October 01, 1989
Immunoglobulin-like domain containing receptor 1 mediates fat-stimulated cholecystokinin secretion. J Clin Invest (2013) 1.05
Cholecystokinin octapeptide stimulates phasic and tonic pyloric motility in healthy humans. Gut (1993) 1.01
Red kidney bean lectin is a potent cholecystokinin releasing stimulus in the rat inducing pancreatic growth. Gut (1997) 0.87
Effects of various food ingredients on gall bladder emptying. Eur J Clin Nutr (2013) 0.87
Role of transient receptor potential channels in cholecystokinin-induced activation of cultured vagal afferent neurons. Endocrinology (2010) 0.84
Impact of ursodeoxycholic acid on a CCK1R cholesterol-binding site may contribute to its positive effects in digestive function. Am J Physiol Gastrointest Liver Physiol (2015) 0.80
Effect of predigested fat on intestinal stimulation of plasma cholecystokinin and gall bladder motility in coeliac disease. Gut (1995) 0.77
Effect of three nonpeptide cholecystokinin antagonists on human isolated gallbladder. Dig Dis Sci (2001) 0.76
Unexpected relationship between plasma protein binding and the pharmacodynamics of 2-NAP, a CCK1-receptor antagonist. Br J Clin Pharmacol (2006) 0.75
Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist. Br J Pharmacol (1996) 0.75
THE TWO-PERIOD CHANGE-OVER DESIGN AN ITS USE IN CLINICAL TRIALS. Biometrics (1965) 15.61
Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest (1985) 2.64
A critical evaluation of real-time ultrasonography for the study of gallbladder volume and contraction. Gastroenterology (1980) 2.39
Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc Natl Acad Sci U S A (1986) 2.34
Feedback regulation of pancreatic enzyme secretion as a mechanism for trypsin inhibitor-induced hypersecretion in rats. Proc Soc Exp Biol Med (1972) 1.89
Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin. Proc Natl Acad Sci U S A (1986) 1.53
Regulation of gastric emptying in humans by cholecystokinin. J Clin Invest (1986) 1.31
Technical factors in gastric emptying studies. J Nucl Med (1983) 1.24
Proteins but not amino acids, carbohydrates, or fats stimulate cholecystokinin secretion in the rat. Am J Physiol (1986) 1.21
Feedback regulation of pancreatic enzyme secretion. Suppression of cholecystokinin release by trypsin. J Clin Invest (1986) 1.21
CHOLECYSTOKININ-PANCREOZYMIN EXTRACTS AND GASTRIC MOTOR INHIBITION. Surg Gynecol Obstet (1965) 1.12
In vivo pharmacology of L-364,718, a new potent nonpeptide peripheral cholecystokinin antagonist. J Pharmacol Exp Ther (1987) 1.03
Regulation of the release of cholecystokinin by bile salts in dogs and humans. Gastroenterology (1988) 1.01
Plasma cholecystokinin responses after ingestion of liquid meal and intraduodenal infusion of fat, amino acids, or hydrochloric acid in man: analysis with region specific radioimmunoassay. Am J Gastroenterol (1983) 0.95
In the absence of nutrients, pancreatic-biliary secretions in the jejunum do not exert feedback control of human pancreatic or gastric function. J Lab Clin Med (1980) 0.94
Production of rabbit antibody specific for amino-terminal residues of cholecystokinin octapeptide (CCK-8) by selective suppression of cross-reactive antibody response. J Immunol Methods (1982) 0.93
Cholecystokinin is a physiological hormonal mediator of fat-induced inhibition of gastric emptying in man. Eur J Clin Invest (1988) 0.92
Action of the cholecystokinin antagonist L364,718 on gastric emptying in the rat. Am J Physiol (1988) 0.92
A new simple mouse model for the in vivo evaluation of cholecystokinin (CCK) antagonists: comparative potencies and durations of action of nonpeptide antagonists. Life Sci (1986) 0.85
Noncholecystokinin peptides in human serum which cause gallbladder contraction. Life Sci (1982) 0.85
Validation of corrections for errors in collimation during measurement of gastric emptying of nuclide-labeled meals. J Nucl Med (1983) 0.84
Jejunal bypass stimulation of pancreatic growth and cholecystokinin secretion in rats: importance of luminal nutrients. Gut (1987) 0.81
Plasma cholecystokinin-octapeptide like immunoreactivity in patients with hepatic cirrhosis. Life Sci (1987) 0.80
Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med (2000) 2.82
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation (2001) 2.55
Peculiar body composition in patients with Prader-Labhart-Willi syndrome. Am J Clin Nutr (1997) 2.23
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med (1999) 2.18
Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther (1999) 2.10
A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer (2007) 2.07
High Fas ligand expression on lymphocytes in lesions of ulcerative colitis. Gut (1998) 1.88
Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol (2000) 1.70
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer (2001) 1.65
Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res (1999) 1.63
Diagnosis of pericardial effusion by ultrasound. Br Med J (1968) 1.62
Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects. J Clin Endocrinol Metab (1994) 1.55
A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology (1998) 1.52
Morphological and functional restoration of parietal cells in helicobacter pylori associated enlarged fold gastritis after eradication. Gut (1999) 1.44
STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells. Int J Cancer (1998) 1.41
Serum pepsinogen I levels and acid secretion in Helicobacter pylori associated enlarged fold gastritis. Ital J Gastroenterol (1997) 1.40
Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res (1997) 1.35
Pharmacokinetics of alendronate. Clin Pharmacokinet (1999) 1.31
Regulation of gastric emptying in humans by cholecystokinin. J Clin Invest (1986) 1.31
Increased production of interleukin 1 beta and hepatocyte growth factor may contribute to foveolar hyperplasia in enlarged fold gastritis. Gut (1996) 1.26
Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. J Clin Endocrinol Metab (1997) 1.25
Renal effects of COX-2-selective inhibitors. Am J Nephrol (2001) 1.24
Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther (1999) 1.22
Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology (Oxford) (2002) 1.20
Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol (2001) 1.19
Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther (2002) 1.12
The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab (1993) 1.11
Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res (1996) 1.11
Interleukin-1 beta inhibits gastric histamine secretion and synthesis in the rat. Am J Physiol (1994) 1.11
Mutations of the bak gene in human gastric and colorectal cancers. Cancer Res (2000) 1.10
Influence of body composition on bone mineral content in children and adolescents. Am J Clin Nutr (1996) 1.09
Improved fold width and increased acid secretion after eradication of the organism in Helicobacter pylori associated enlarged fold gastritis. Gut (1994) 1.09
Localization of heparin-binding epidermal growth factor-like growth factor in human gastric mucosa. Gastroenterology (1995) 1.08
Inter- and intrachromosomal rearrangements are both involved in the origin of 15q11-q13 deletions in Prader-Willi syndrome. Am J Hum Genet (1997) 1.07
A quantitative index of intracranial cerebrospinal fluid distribution in normal pressure hydrocephalus using an MRI-based processing technique. Neuroradiology (2000) 1.05
Helicobacter pylori increases gene expression of hepatocyte growth factor in human gastric mucosa. Biochem Biophys Res Commun (1995) 1.04
Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. Clin Pharmacol Ther (1999) 1.04
Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group. J Rheumatol (1999) 1.04
Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur J Clin Pharmacol (2000) 1.02
Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability. Br J Clin Pharmacol (1997) 1.01
Hypogonadism and pubertal development in Prader-Willi syndrome. Eur J Pediatr (2003) 0.99
The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin. Clin Pharmacol Ther (2000) 0.98
A survey on Prader-Willi syndrome in the Italian population: prevalence of historical and clinical signs. J Pediatr Endocrinol Metab (2009) 0.97
Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab (2001) 0.97
Persisting obesity starting before puberty is associated with stable intraabdominal fat during adolescence. Int J Obes Relat Metab Disord (1999) 0.97
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab (1998) 0.96
Montelukast dose selection in 6- to 14-year-olds: comparison of single-dose pharmacokinetics in children and adults. J Clin Pharmacol (1999) 0.96
Gastrin induces heparin-binding epidermal growth factor-like growth factor in rat gastric epithelial cells transfected with gastrin receptor. Gastroenterology (1999) 0.96
Over-expression of bcl-xL gene in human gastric adenomas and carcinomas. Int J Cancer (1996) 0.95
Plasma cholecystokinin responses after ingestion of liquid meal and intraduodenal infusion of fat, amino acids, or hydrochloric acid in man: analysis with region specific radioimmunoassay. Am J Gastroenterol (1983) 0.95
Malignant transformation of intrathoracic ancient neurilemoma in a patient without von Recklinghausen's disease. Acta Pathol Jpn (1982) 0.94
Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity. J Clin Pharmacol (1999) 0.94
Comparison between MR imaging and 99mTc MIBI scintigraphy in the evaluation of recurrent of persistent hyperparathyroidism. Radiology (2001) 0.93
An increased number of CD40-high monocytes in patients with Crohn's disease. Am J Gastroenterol (2000) 0.92
The clinical and molecular characterization of patients with dyshormonogenic congenital hypothyroidism reveals specific diagnostic clues for DUOX2 defects. J Clin Endocrinol Metab (2013) 0.92
Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. Br J Clin Pharmacol (1997) 0.90
Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile. Drug Metab Dispos (1997) 0.90
Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production. Gastroenterology (2001) 0.90
Role of prostaglandins in intestinal epithelial restitution stimulated by growth factors. Am J Physiol (1996) 0.89
Activation of mammalian target of rapamycin in postmenopausal ovarian endometriosis. Int J Gynecol Cancer (2006) 0.88
Induction of heparin binding epidermal growth factor-like growth factor and amphiregulin mRNAs by gastrin in the rat stomach. Biochem Biophys Res Commun (1997) 0.88
Insulin-sparing effects of pancreatic polypeptide in congenitally obese rodents. Pancreas (1991) 0.88
Evaluation of sentinel lymph node status in spindle cell melanomas. J Am Acad Dermatol (2001) 0.88
Gene for the rat atrial natriuretic peptide is regulated by glucocorticoids in vitro. J Clin Invest (1988) 0.87
Assessment of MK-912, an alpha 2-adrenoceptor antagonist, with use of intravenous clonidine. Clin Pharmacol Ther (1989) 0.87
GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology. J Endocrinol Invest (2000) 0.87
Peripheral nerve abnormalities in newly-diagnosed diabetic children. Acta Diabetol Lat (1986) 0.87
Hunger in humans induced by MK-329, a specific peripheral-type cholecystokinin receptor antagonist. Biol Psychiatry (1990) 0.86
Phantom studies for estimation of defect size on cardiac (18)F SPECT and PET: implications for myocardial viability assessment. J Nucl Med (2001) 0.86
Substance P-induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man. Br J Clin Pharmacol (1999) 0.86
Sestamibi scanning is inadequate for directing unilateral neck exploration for first-time parathyroidectomy. Arch Surg (1997) 0.86
Mucosal interleukin-1 beta production and acid secretion in enlarged fold gastritis. Aliment Pharmacol Ther (1997) 0.85
Relative expansion of extracellular water in obese vs. normal children. J Appl Physiol (1985) (1995) 0.85
A case of squamous cell carcinoma of the pancreas with an initial symptom of tarry stool. J Gastroenterol Hepatol (2001) 0.85
Micrometastasis to in-transit lymph nodes from extremity and truncal malignant melanoma. Ann Surg Oncol (2001) 0.85
Expression of hepatocyte growth factor and c-met in ulcerative colitis. Inflamm Res (2000) 0.84
Polymyositis and toxoplasmosis. Acta Pathol Jpn (1981) 0.84
Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis. Ann Rheum Dis (2004) 0.84
Thyroid hormone increases rat atrial natriuretic peptide messenger ribonucleic acid accumulation in vivo and in vitro. Mol Endocrinol (1987) 0.83
Effects of bifonazole, fluconazole, itraconazole, and terbinafine on the chemiluminescence response of immune cells. J Antimicrob Chemother (1987) 0.83
Chronic administration of corticotropin-releasing factor increases pituitary corticotroph number. Endocrinology (1987) 0.83
Analysis of gene expression in apoptosis of human lymphoma U937 cells induced by heat shock and the effects of alpha-phenyl N-tert-butylnitrone (PBN) and its derivatives. Apoptosis (2005) 0.82
Prader-Willi syndrome: relationship of adiposity to plasma leptin levels. Obes Res (1998) 0.82
Role of heparin-binding EGF-related peptides in proliferation and apoptosis of activated ras-stimulated intestinal epithelial cells. Int J Cancer (1997) 0.82
Physiological role for cholecystokinin in reducing postprandial hyperglycemia in humans. J Clin Invest (1988) 0.82
The gastrin-receptor antagonist L-365,260 inhibits stimulated acid secretion in humans. Clin Pharmacol Ther (1993) 0.81
Regulation of pancreatic endocrine function by cholecystokinin: studies with MK-329, a nonpeptide cholecystokinin receptor antagonist. J Clin Endocrinol Metab (1990) 0.81
Short-term subcutaneous insulin infusion in diabetic children. Comparison with three daily insulin injections. Acta Diabetol Lat (1983) 0.81
Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. J Clin Oncol (1993) 0.81
Systemic melioidosis presenting as myocardial infarct. Ann Intern Med (1967) 0.81
Met/HGF receptor modulates bcl-w expression and inhibits apoptosis in human colorectal cancers. Br J Cancer (2000) 0.81
Pharmacokinetics of intravenous alendronate. J Clin Pharmacol (1999) 0.80
Heparin-binding EGF-like growth factor is an autocrine growth factor for rat gastric epithelial cells. Biochem Biophys Res Commun (1996) 0.80
Rationale for the use of alendronate in osteoporosis. Osteoporos Int (1995) 0.80
Metabolic control in newly diagnosed type 1 diabetic children. Effect of continuous subcutaneous infusion. Horm Res (1984) 0.80
Bone mass in young patients with type I diabetes. Bone Miner (1990) 0.80